PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Darifenacin hydrobromide - Overactive bladder (adults)
PAD Profile : Darifenacin hydrobromide - Overactive bladder (adults) Important
Keywords :
OAB, urinary frequency, urge incontinence, LUTS, lower urinary tract symptoms, urinary incontinence, anticholinergics, antimuscarinics
Brand Names Include :
Emselex
Important Information :
Switch to solifenacin recommended (if appropriate)
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Flavoxate hydrochloride
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Fesoterodine fumarate
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section.
05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Darifenacin is non-formulary.
The APC agreed that darifenacin could be switched to solifenacin or an alternative formulary treatment option if solifenacin is contraindicated:
- In patients with reduced renal function
- Patients with CNS adverse effects (confusion, drowsiness, halucinations)
- Where there is the potential of interactions at Cytochrome P450 3A4
- in patients where anticholinergics are contraindicated
- In patients that require a more potent treatment
See Selection Tool for locally agreed OAB treatments.
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence